RCS - Oxford Biomedica PLC - Licensing agreement with VVMF

Oxford BioMedicaAnnouncement

18/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260318:nRSR0452Xa&default-theme=true

RNS Number : 0452X  Oxford Biomedica PLC  18 March 2026

 

 

 

OXB enters into licensing agreement with Viral Vector Manufacturing Facility
(VVMF), providing access to its AAV and LV viral vector platforms

-       Next step in a broader collaboration to support VVMF build viral
vector manufacturing capabilities

Oxford, UK - 18 March 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that it has entered
into a licensing and option agreement with Viral Vector Manufacturing Facility
(VVMF), an Australian CDMO and the country's first commercial manufacturing
facility of its kind.

 

Further to the non-binding terms sheet signed in October 2025, this agreement
provides VVMF with a worldwide, non-exclusive licence to OXB's proprietary
inAAVate™ platform know-how and intellectual property, with an option to
extend the licence to its proprietary LentiVector™ platform. In return, OXB
will receive a low single-digit million licence fee and is eligible for future
payments related to the use of its platforms.

 

This five-year licence underpins the strategic collaboration between OXB and
VVMF, enabling VVMF to accelerate its operational and commercial readiness to
provide advanced viral vector technologies to customers, capturing global
demand with a particular focus on the fast-growing APAC region, and
positioning Australia as a regional hub for high‑quality cell and gene
therapy manufacturing.

By collaborating with VVMF, OXB is extending the global reach of its
platforms, reinforcing its position as a trusted provider of viral vector
development and manufacturing services. The agreement highlights the
scalability and reliability of OXB's platforms and technologies and reflects
growing international recognition of its expertise.

 

Dr Sébastien Ribault, Chief Business Officer of OXB, said: "This agreement is
a strong endorsement of OXB's position as a world-leading viral vector CDMO.
It demonstrates the robustness and adaptability of our platforms,
technologies, and quality systems, enabling other organisations to benefit
from the high standards we've established in viral vector manufacturing.
Partnering with VVMF not only gives us a strategic foothold in Australia but
also creates a launchpad to serve clients across the APAC region, further
strengthening the global foundation for reliable AAV and lentiviral vector
production".

 

Stephen Thompson, Chief Executive Officer of VVMF, added: "Access to the OXB
platforms gives us a strong foundation as we continue to build our
capabilities, leveraging OXB's expertise and global brand recognition to
establish a leadership position in the APAC region. The collaboration will
help us accelerate operational readiness and ensure our processes are aligned
with recognised industry standards. We look forward to working closely with
the OXB team as we establish reliable and scalable manufacturing
capabilities."

 

-Ends-

 

Enquiries:

 

OXB:

Sebastien Ribault, Chief Business Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com (mailto:partnering@oxb.com)

VVMF:

 

E: media@vvmf.com.au (mailto:media@vvmf.com.au)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

 

 

About VVMF - Unlocking the Future of Medicine

 

Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia's only
Contract Development and Manufacturing Organisation (CDMO) dedicated to
providing services in the research, design, development, and manufacture of
viral vectors for advanced therapeutic applications. VVMF partners with
researchers, clinicians, and bio-pharma companies to accelerate the path to
market for cell and gene therapies to local and global patients.

 

Viral vectors play a crucial role in delivering genetic material into cells
and are central to innovative treatments in areas of medicine including
cancers and rare diseases.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAFDXFFXKEAA



            Copyright 2019 Regulatory News Service, all rights reserved